6 assets in Atypical Endometrial Hyperplasia

Therapeutic assets addressing Atypical Endometrial Hyperplasia, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Pegloxenatide Atypical Endometrial Hyperplasia	Fudan University	P2/3	B (61)
Letrozole Atypical Endometrial Hyperplasia	Xiaojun Chen	P2/3	B (57)
Metformin Atypical Endometrial Hyperplasia	Xiaojun Chen	P2/3	B (57)
Levonorgestrel Atypical Endometrial Hyperplasia	Xiaojun Chen	P2/3	CCC (55)
Megestrol Acetate Atypical Endometrial Hyperplasia	Xiaojun Chen	P2/3	CCC (55)
Tirzepatide Atypical Endometrial Hyperplasia	National Cancer Institute (NCI)	P2	CCC (53)